Vertical Aerospace
UK eVTOL developer building the VX4, a four-passenger electric air taxi targeting EASA and UK CAA certification.
1 article
Vertical Aerospace
Vertical Aerospace is a Bristol, UK-based developer of the VX4, an electric vertical-takeoff-and-landing aircraft designed for a pilot and four passengers. The company trades on the NYSE as EVTL. It is pursuing UK Civil Aviation Authority certification, with a route to validation in other markets, and remains pre-commercial.
Key Products
- VX4 - Five-seat eVTOL with a wing and distributed electric propulsion. Published range and cruise-speed figures are design targets, not operating specifications for a certificated aircraft. Vertical’s current public materials describe a target to certify the VX4 by 2028, subject to certification and development risk.
Business and Funding
Vertical became public through a 2021 SPAC transaction. It has repeatedly needed external capital to fund development and has disclosed going-concern risk in prior filings. Its 2026 funding needs and certification timetable should be assessed from its current filings rather than earlier conditional-order announcements. No current aircraft-sales revenue is reported in this profile.
The company reported a business update for the first half of 2026, including continued work on its flight-test programme. Its partners and conditional aircraft commitments indicate commercial interest, but they are not aircraft deliveries or booked operating revenue.
Why It Matters
Vertical is one of the few publicly traded European eVTOL developers with a full-scale aircraft programme. It matters as a test of whether a European developer can finance an extended certification campaign while maintaining industrial partners and flight-test momentum. The central question is not the size of historic pre-order announcements; it is whether the company can secure sufficient capital, demonstrate the VX4 safely and satisfy the regulator’s certification basis. Those outcomes remain unresolved, so company targets are kept distinct from reported results.
